Safety assessment of a new nanoemulsion-based drug-delivery system reveals unexpected drug-free anticoagulant activity.
Nanomedicine (Lond)
; 15(14): 1361-1373, 2020 06.
Article
in En
| MEDLINE
| ID: mdl-32484393
ABSTRACT
Aim:
A preclinical safety assessment of a novel nanoemulsion drug-delivery system, initially developed to improve the posology of efavirenz (EFV), was conducted with a specific focus on possible immunological and hematological complications. Materials &methods:
Assessment of common acute toxicities, such as complement activation and cytokine secretion, was performed using validated assays known to have good correlation with in vivo end points. Results &conclusion:
Compared with a standard aqueous solution of EFV, the EFV nanoemulsion showed no significant effect on immune cell function or phenotype. Prolongation of activated partial thromboplastin time was observed for EFV-loaded nanoemulsions (88% at 4 µg/ml) as well as unloaded nanoemulsions (52%) highlighting the potential for drug-free anticoagulant activity and warranting further investigation of the mechanism and utility of these materials.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Drug Carriers
/
Drug Delivery Systems
Language:
En
Journal:
Nanomedicine (Lond)
Year:
2020
Document type:
Article
Affiliation country:
United kingdom